CHICAGO–Exposure to aspirin after diagnosis of colorectal cancer is independently associated with improved colorectal cancer-specific survival and overall survival, data presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting have shown.
Researchers identified 25,644 patients diagnosed with colorectal cancer between 2004 and 2011 from the Cancer Registry of Norway and 6,109 of them were defined as exposed to aspirin after the diagnosis of colorectal cancer.
Simer Bains, MD, PhD Fellow at the University of Oslo and the Centre for Molecular Medicine in Norway said, “Compared with nonusers, more aspirin users were older and male, had well to moderate tumor differentiation, and had less advanced disease stage.”
Results showed that during a median follow-up of 2.2 years, there was a total of 2,088 deaths among aspirin users. Of those, 1,172 were colorectal cancer-specific. Among non-aspirin users, there were a total of 7,595 deaths of which 6,356 were related to colorectal cancer.
Researchers found that in multivariate analysis, aspirin exposure after the diagnosis of colorectal cancer was independently associated with improved colorectal cancer-specific survival (HR=0.75; 95% CI: 0.70, 0.81; P<0.001) and overall survival (HR=0.86; 95% CI: 0.81, 0.91; P<0.001).
Previous studies have demonstrated an association between regular use of aspirin and a reduced incidence and mortality of colorectal cancer, but the findings of this study suggest that aspirin should be further evaluated as secondary prevention in patients with colorectal cancer.
“Use of aspirin after the diagnosis of colorectal cancer increased both overall and colorectal cancer-specific survival in a cohort of 25,644 Norwegian patients,” Dr. Bains concluded.
1. Bains S, Mahic M, Cvancarova M, et al. Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study.
J Clin Oncol. 2015;33:(suppl; abstr 3504).